Clinical validation for LOXO-101 against TRK fusion cancer

27 julio 2015

The first imaging studies of TRK fusion cancer conducted post-treatment have confirmed that stage IV patient’s tumors had substantially regressed. With four months of treatment, additional CT scans have demonstrated almost complete disappearance of the largest tumors.img src=»http://feeds.feedburner.com/~r/sciencedaily/~4/z6QXlYBVq7g» height=»1″ width=»1″ alt=»»/
http://feeds.sciencedaily.com/~r/sciencedaily/~3/z6QXlYBVq7g/150727180229.htm

Volver